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To identify endocytic receptors that allow dendritic cells (DCs) to capture and present antigens
on major histocompatibility complex (MHC) class I products in vivo, we evaluated DEC-205,
which is abundant on DCs in lymphoid tissues. Ovalbumin (OVA) protein, when chemically
coupled to monoclonal DEC-205 antibody, was presented by CD11c lymph node DCs, but
not by CD11c cells, to OVA-specific, CD4 and CD8 T cells. Receptor-mediated presentation was at least 400 times more efficient than unconjugated OVA and, for MHC class I, the
DCs had to express transporter of antigenic peptides (TAP) transporters. When DEC-205:OVA
was injected subcutaneously, OVA protein was identified over a 4–48 h period in DCs, primarily in the lymph nodes draining the injection site. In vivo, the OVA protein was selectively
presented by DCs to TCR transgenic CD8 cells, again at least 400 times more effectively than
soluble OVA and in a TAP-dependent fashion. Targeting of DEC-205:OVA to DCs in the
steady state initially induced 4–7 cycles of T cell division, but the T cells were then deleted and
the mice became specifically unresponsive to rechallenge with OVA in complete Freund’s adjuvant. In contrast, simultaneous delivery of a DC maturation stimulus via CD40, together
with DEC-205:OVA, induced strong immunity. The CD8 T cells responding in the presence of agonistic CD40 antibody produced large amounts of interleukin 2 and interferon ,
acquired cytolytic function in vivo, emigrated in large numbers to the lung, and responded vigorously to OVA rechallenge. Therefore, DEC-205 provides an efficient receptor-based mechanism for DCs to process proteins for MHC class I presentation in vivo, leading to tolerance in
the steady state and immunity after DC maturation.
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Introduction
The immune system resists pathogens while remaining tolerant of self-antigens and innocuous proteins in the environment. Immune tolerance can be maintained by both
central and peripheral mechanisms. Central tolerance for T
cells is established in the thymus, where self-reactive T cells
can be deleted (1–3), e.g., after an encounter with antigen
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on the surface of thymic medullary dendritic cells (DCs)*
(4–6). Peripheral tolerance mechanisms are required in situations where central tolerance is incomplete and for antigens that do not access the thymus, e.g., environmental
proteins typically found at body surfaces like the airway and
intestine (for reviews, see references 7–10). DCs in the periphery continuously capture proteins from the airway and
intestine (11, 12) and are anatomically positioned to present
these antigens to T cells in lymphoid organs (13, 14). A
*Abbreviations used in this paper: CFSE, carboxyfluorescein diacetate succinimidyl ester; DC, dendritic cell.
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Materials and Methods
Antibodies. Antibodies to CD45.1 (A20) and other cell
surface markers (CD8/53–6.7, CD62L/MEL-14, CD80/16–
10A1, CD86/GL1, MHC class II I-Ab/AF6–120.1) including
TCR specificities (V5.1/5.2/MR9–4; V2/B20.1) were purchased from BD Biosciences. Hybridomas producing antibodies
were obtained from the American Type Culture Collection including DEC-205/CD205 (NLDC-145 HB 290), GL-117 (a
nonreactive rat IgG2a isotype match for DEC-205), CD107a/
LAMP-1, MHC class II (M5/114, TIB120), F4/80 (HB 198),
NK1.1, B220 (RA3–6B2), CD4 (GK1.5, TIB 207), CD8 (53.6.7
TIB 105), and CD11c (N418, HB224). Agonistic CD40
FGK45.5 mAb was provided by Dr. T. Rolink (Basel Institute
for Immunology, Basel, Switzerland). Magnetic microbeads were
from Miltenyi Biotec.
Mice. C57BL/6 (B6) mice were obtained from Taconic and
TAP/ mice from The Jackson Laboratory. OT-I mice were
provided by Dr. F. Carbone (University of Melbourne, Parkville,
Victoria, Australia) and OT-II were obtained from the Trudeau
Institute. CD45.1 OT-I mice were produced by crossing OT-I
to B6.SJL-Ptprc mice (The Jackson Laboratory).
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Conjugation of OVA to Monoclonal Antibodies. Purified IgGs
were conjugated to maleimide activated OVA (Pierce Chemical Co.) or LPS-free OVA (Seikagaku Corporation) activated
with Sulfo-SMCC (sulfosuccinimidyl 4-(N-maleimidomethyl)
cyclohexane-1-carboxylate; Pierce Chemical Co.) using the
manufacturer’s protocol. Antibody:OVA conjugates prepared
with OVA from both sources gave similar results in terms of
DC targeting and T cell responses in vivo. Although it is difficult to exclude some contamination with LPS in our preparations, the DCs in mice injected with antibody conjugates did
not show evidence for maturation, as occurs when LPS is administered to mice. For coupling, the antibodies were reduced
using 2-mercapto-ethanolamine:HCl and separated from the
reducing agent over a desalting column. Then maleimide-activated OVA was mixed with the reduced antibodies overnight
at 4C. The antibody:OVA conjugates were passed over a protein G column to remove unconjugated OVA, concentrated by
spin columns (Millipore) and evaluated by spectrophotometry
and SDS-PAGE.
Isolation of DCs and Antigen-specific T Cells. Popliteal, inguinal, axillary, and brachial LNs were removed from adult female B6 or TAP/ mice. Single cell suspensions were prepared
with 400 U/ml collagenase for 25 min (Roche). The cells were
incubated with anti–mouse CD11c or CD19 MACS® microbeads for 30 min on ice. CD11c (DC-enriched), CD19 (B
cell-enriched), and double negative cells were separated by application of a magnetic field and dispensed into 48-well plates at
5  105 cells/well. Cells were cultured with antigen overnight
(16–20 h) at 37C and washed twice in PBS before use as antigen presenting cells for naive TCR transgenic, OVA-specific T
cells. Bone marrow DCs were prepared with GM-CSF as described previously (34). 6 d after bone marrow harvest, the DCs
were dislodged, washed, and pulsed with antibody:OVA conjugate (10 g/ml) for 6 h before coculture with T cells. CD8 or
CD4 T cells were prepared from OT-I or OT-II mice, respectively. OT-I and OT-II T cells were purified from single cell
suspensions of lymph node or spleen cells by negative selection
using hybridoma supernatants (above) directed against MHC-II,
F4/80, B220, NK 1.1, and CD4 or CD8 and goat anti–rat
Dynabeads® (Dynal) at a ratio of 4 beads to 1 target cell. Culture
medium was RPMI, 7% FBS, 100 U/ml penicillin streptomycin
mixture, 0.25 mg/ml fungizone, 10 mM HEPES, and 55 M
-mercaptoethanol. To identify OT-I cells in the lung, single
cell suspensions were prepared by flushing the vascular system of
the lung with 10 ml PBS and 10 U/ml heparin (Elkins-Sinn)
through the right ventricle and dissociating the tissue in a 70 m
Cell Strainer® (Becton Dickinson).
In Vivo Capture of Antibody:OVA Conjugates. B6 or TAP/
mice were injected with graded doses of IgG:OVA conjugates
or soluble OVA in the paws subcutaneously. Lymph nodes
(popliteal, inguinal, axillary, and brachial) were harvested 1–4 d
later and the DCs isolated (as above) to test for antigen presentation to OT-I cells in vitro. 105 T cells were added to graded
doses of CD11c DCs, CD11c nonDCs, or CD11cCD5 B
cells in round bottom 96-well plates. [3H]thymidine (1 Ci;
Amersham Biosciences) was added at 48–72 h to detect incorporation into DNA. Data shown are means of triplicates where the
standard deviation was 10% of the mean cpm. To detect
OVA, CD11c or CD11c cells were washed, lysed in SDS
sample buffer for SDS-PAGE, and then aliquots corresponding
to 106 cells transferred to PVDF membranes (Hybond-P; Amersham Biosciences). For immunoblotting, we used HRP-conjugated polyclonal rabbit anti-OVA (Research Diagnostics, Inc.)
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well-studied model involves the presentation of antigens
from insulin producing, pancreatic islet  cells on MHC
class I and II products of DCs in pancreatic lymph nodes
(15–18). However, the experimental induction of peripheral tolerance to proteins presented on MHC class I usually
requires the injection of large amounts of preprocessed
peptides rather than small amounts of intact proteins (19).
Efficient molecular pathways for developing tolerance to
environmental and self-proteins presented on MHC class I
products remain to be defined.
DCs have a number of receptors for adsorptive uptake of
antigens. Some are shared with other cells, such as Fc receptors (20–23) and the macrophage mannose receptor
(24). Other receptors are more DC restricted, e.g., Langerin or CD207 (25), DC-SIGN or CD209 (26, 27), an
asialoglycoprotein receptor (28), and BDCA-2 (29), but at
this time, these receptors have not been shown to mediate
the selective presentation of antigens on the MHC class I
and II products of DCs in vivo. In contrast, DEC-205, an
endocytic receptor with 10 membrane-external, contiguous C-type lectin domains (30, 31), mediates the efficient
processing and presentation of antigens on MHC class II
products in vivo (32). DEC-205 is expressed at high levels
on DCs in the T cell areas of lymphoid organs (13, 33), and
DEC-205 antibodies are available that selectively target
these DCs in mice (32). Here we chemically couple a protein to DEC-205 and demonstrate the capacity of this receptor to deliver endocytosed protein in the absence of infection to the TAP-dependent pathway for MHC class I
peptide loading. Small amounts of injected antigen, targeted to DCs by the DEC-205 adsorptive pathway, are
able to induce solid peripheral CD8 T cell tolerance.
These results identify an efficient receptor-based mechanism for DCs to continually capture antigens for presentation on MHC class I products in the steady state and to
block the development of CD8 T cell reactivity.
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Results
Targeting Protein to DCs In Situ via DEC-205. To examine the potential role of the DEC-205 endocytic receptor to process proteins through the MHC class I pathway,
we first chemically coupled whole OVA protein to DEC205 antibody. OVA is known to be presented on the
H-2Kb MHC class I molecule to CD8 T cells, including
TCR transgenic OT-I T cells (36). After OVA coupling
to rat anti–mouse DEC-205 antibody, free OVA was
removed by purifying the conjugate on protein G columns, yielding mixtures of 1:1 IgG:OVA conjugates
(MW200 kD) and unconjugated antibody (Fig. 1 A).
Based on the observed conjugation efficiency and the 4:1
mass ratio of IgG to OVA, we estimated that 10% of the
conjugate consisted of OVA protein.
To verify that the DEC-205:OVA targeted DCs in
mice, we injected 1 g of the conjugates subcutaneously
and probed for OVA protein in isolated CD11c DCenriched (14, 37) and CD11c DC-depleted, lymph node
cells. Prior work had demonstrated the uptake of rat
DEC-205 antibody by most DCs (32), but here we followed the capture of the OVA protein. Uptake by DCs
plateaued in the draining node within 12–24 h of injection
(Fig. 1, B–D). The 45 kD size of the immunoreactive
OVA in the DCs was similar to native OVA, suggesting
that most of the protein had been released from its conjugation to the injected antibody (Fig. 1 B). Injection of 10
g soluble OVA subcutaneously did not yield detectable
antigen in the lymph nodes draining the site of injection
(Fig. 1 C, left lane). With the DEC-205:OVA conjugate,
OVA was only found in the CD11c DC-enriched fraction and not the CD11c DC-depleted cells (Fig. 1 C).
Smaller amounts of OVA were also detected in DCs in distal sites like lymph nodes and spleen (Fig. 1 D). The
amount of captured OVA corresponded to 10 ng of protein per 106 DCs or 105 molecules/DC (Fig. 1 B). We conclude that protein coupled to DEC-205 antibody is efficiently delivered to DCs in situ.
Isolated Lymph Node DCs Present DEC-205:OVA Conjugates on MHC Class I via TAPs. To determine whether
antigen delivered by DEC-205 to DCs can be processed
for presentation by MHC class I, we first isolated DCs from
lymph nodes and treated them with DEC-205:OVA in
vitro. The antibody:OVA conjugates were incubated with
CD11c and CD11c lymph node cells overnight, excess
conjugate was removed by washing, and then the cells
were cocultured for 2 d with OVA-specific TCR transgenic T cells (CD8 MHC class I–restricted OT-I or
CD4 MHC class II–restricted OT-II T cells). We found
that OVA was presented by CD11c DCs on both MHC
class I and class II products (Fig. 2 A). DCs exposed to 0.1
g/ml of DEC-205:OVA (with 10 ng/ml OVA protein) were more active in presenting to MHC class I restricted CD8 OT-I T cells than DCs that had been exposed to 30 g/ml of soluble OVA (Fig. 2 A). Uptake via
DEC-205 increased the efficiency of presentation relative
to unconjugated OVA at least 1,000-fold for MHC I and
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diluted in Roti-Block® (Carl Roth) visualized by ECL® (Amersham Biosciences).
Flow Cytometry. Multicolor flow cytometry was used to
monitor three functional responses as described in the following
sections: proliferation of carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled T cells as assessed by progressive halving of the amount of fluorescence per cell; maturation of DCs as
assessed by up-regulation of surface antigens like CD80, CD86,
and MHC II; and induction of T cell effector function, i.e., accumulation of intracellular cytokines and expression of CTL activity. We used a FACSCalibur™ (BD Biosciences) with subsequent analysis of data in CELLQuest™ (BD Biosciences) or
FlowJo® (Tree Star).
Labeling of T Cells with CFSE for In Vivo T Cell Proliferative Responses. OT-I T cells at 107 cells/ml were incubated with
CFSE (Molecular Probes; 5 M) for 10 min at 37C. An equal
volume of FCS was added, and the cells washed two times
with PBS/0.1% BSA and once with PBS. 2  106 labeled OT-I
T cells were injected intravenously into B6 recipients. 24 h
later, antibody:OVA conjugates were injected into all 4 paws
with or without agonistic CD40 antibody, 100 g subcutaneously. After 3 d, lymph node suspensions were stained for
V5.1/5.2, V2, and CD8 and evaluated by multicolor flow cytometry.
In Vivo DC Maturation. 100 g of CD40 was injected subcutaneously into B6 mice that had or had not received antibody:
OVA conjugates and OT-I T cells. 1–3 d later, lymph node
CD11c cells were isolated by staining with PE-conjugated
CD11c and separation with anti-PE microbeads and MACS®.
CD11c cells were stained for CD80, CD86, or I-Ab (MHC II)
and evaluated by flow cytometry. In some experiments, the
CD11c cells were double labeled with biotin-DEC-205 to
follow DEC-205 high and low expressing subsets of DCs.
In Vivo T Cell Effector Responses. 106 CD45.1 OT-I T cells
were purified (above) and injected intravenously into B6 mice.
24 h later, antibody:OVA conjugates with or without CD40
were injected. 3 and 12 d later, lymph node suspensions were
stained for surface CD45.1, V5.1/5.2, CD62L, intracellular IL-2
(JES6–5H4), or IFN- (XMG1.2). 5  106 lymph node cells
were pulsed in 24-well dishes with the OT-I cognate peptide
(SIINFEKL) for 5 h in the presence of brefeldin A (SigmaAldrich). Cells were then harvested, washed twice with PBS/2%
FBS, and stained for extracellular CD45.1 and V5.1/5.2. These
cells were then fixed and stained for cytokines with the BD Biosciences Intracellular Cytokine Staining Starter Kit as per the
manufacturer’s protocol.
In vivo CTL assays were performed as described previously
(35) by injecting 1:1 mixtures of peptide-pulsed and unpulsed
syngeneic splenocytes (3  10 6 each) labeled with 5 M
(CFSEhi) and 0.5 M (CFSElo) CFSE, respectively, as described
above. 12 h later, single cell suspensions from lymph nodes were
evaluated by flow cytometry. Specific killing was evaluated by
the reduction of the CFSEhi population without any reduction of
the CFSElo population relative to control mice lacking OT-I T
cells.
Tests for Immune Tolerance. Mice were given OT-I T cells
and IgG:OVA conjugates with or without CD40 (see above).
12 d after antigen injection, mice were boosted with OVA protein (50 g subcutaneously; Calbiochem) suspended in complete Freund’s adjuvant (Difco). 3 d later, mice were killed and
lymph nodes harvested for either in vitro restimulation and intracellular IL-2 and IFN- staining, or in vivo CTL assays
(above).
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300-fold for MHC II (Fig. 2 A). In contrast, neither
CD19 B cells nor APCs depleted of CD11c and CD19
cells were able to stimulate T cell proliferation above background levels, even at cell doses 30-fold higher than those
required to observe presentation by DCs (Fig. 2 B). Isotype
control IgG:OVA conjugates were much less active than
DEC-205:OVA conjugates (Fig. 2 B).
Several additional controls (data not depicted) were performed to verify the function of the DEC-205 receptor in
the presentation of protein conjugated to the corresponding
monoclonal antibody. Because DCs can utilize Fc receptors to present immune complexes on MHC class I products
(20, 21), we showed that blocking these receptors (at least
CD16 and CD32) with 2.4G2 FcR monoclonal antibody
(38) did not reduce presentation of DEC-205:OVA. To
evaluate another antibody:OVA conjugate that targets the
endocytic system, we used LAMP-1, a lysosome-associated
membrane protein expressed in DCs and other cells. The
LAMP-1:OVA conjugate was only comparable to isotype
control antibody:OVA in bringing about the presentation of
OVA peptides in the context of either MHC-I or -II by
CD11c DCs. Conjugation was essential for efficient OVA
targeting since mixtures of unconjugated DEC-205 and
soluble OVA were only presented with a comparable efficiency to equivalent doses of soluble OVA, ruling out the
possibility that DEC-205 was simply enhancing presentation of nonconjugated OVA. In summary, the DEC-205 re1630

ceptor mediates efficient presentation of protein antigens on
both MHC class I and II products of lymph node DCs.
To establish that MHC class I presentation by DEC205:OVA was TAP dependent, we performed similar experiments with DCs obtained from TAP-deficient mice
(TAP/; Fig. 2 C). In the absence of TAP, proteosomeprocessed peptides in DCs fail to move into the endoplasmic reticulum for association with MHC I molecules. We
found that TAP/ DCs were unable to present OVA on
MHC class I after uptake of DEC-205:OVA, but the
same cells presented OVA on MHC class II (Fig. 2 C).
Also, the TAP/ DCs could present preprocessed OVA
peptide to MHC class I restricted OT-I T cells (data not
depicted). Thus, antigens endocytosed via DEC-205 are
routed to the MHC class I processing machinery by a pathway that requires transport of peptides from the cytoplasm
to the endoplasmic reticulum.
In contrast to DCs obtained from the lymph node, DEC205 expressing DCs generated from bone marrow progenitors with GM-CSF were only able to present the DEC205:OVA conjugates to OVA-specific CD4 OT-II T cells
but not CD8 OT-I T cells (Fig. 2 D). Therefore, the type
of DC influences the capacity of DEC-205 to deliver antigens for TAP dependent MHC class I presentation.
DEC-205–mediated MHC Class I Presentation In Vivo.
To determine if DCs targeted with DEC-205:OVA also
present OVA peptides on MHC class I in vivo, we next
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Figure 1. Conjugation and delivery of
OVA via monoclonal antibodies. (A) OVA
conjugated and unconjugated IgGs resolved by SDS-PAGE and stained with
Coomassie blue. (B) Immunoblotting with
anti-OVA antibody to detect OVA in the
Ig:OVA conjugates and in CD11c lymph
node DCs (106/lane), the latter at 12 and
24 h after subcutaneous injection of 1 g of
DEC-205:OVA or isotype control:OVA.
(C) The subcutaneous injection of 1 g of
DEC-205:OVA per footpad, but not 10
g of soluble OVA, targets CD11c lymph
node DCs. 106 CD11c cells from the
draining nodes per lane were immunoblotted 12–72 h after injection. (D) DEC205:OVA uptake occurs primarily in
CD11c DCs in the draining lymph nodes.
As in C, but cell fractions were prepared
from draining lymph nodes, distal (Dist.)
nodes and spleen (Spl.).
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isolated CD11c and CD11c cells (or B cells enriched
from the CD11c population by depleting CD5 T cells)
from mice injected subcutaneously with conjugates or with
soluble OVA, and then we assayed for antigen presentation
to OT-I cells in vitro without further addition of antigen.
After injection of DEC-205:OVA, we detected strong
presentation at 4 and 24 h after injection, but only by DCs
(Fig. 3 A, left) and not by CD11c or enriched B cells (Fig.
3 A, right). The B cells also were inactive when the animals
were given CD40 antibody (together with antibody:
OVA) to enhance their costimulatory properties (data not
depicted). 100-fold higher doses of soluble OVA relative to
DEC-205:OVA (which is 10% OVA) were required to
detect presentation, but again the DCs selectively presented
the antigen. This presentation was greater when the cells
were isolated 24 h rather than 4 h after injection (Fig. 3 A).
After injection of DEC-205:OVA, presentation was
readily detected for as long as 4 d (Fig. 3 B). The presentation by DCs in vivo was TAP dependent (Fig. 3 C). In
contrast, antibody:OVA conjugates directed toward other
1631
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DC markers, e.g., MHC-II and LAMP-1, did not enhance
OVA-presentation (Fig. 3 D). In all experiments, there was
little or no capture of the isotype-control:OVA conjugate
(Figs. 3, B–D).
To verify that DCs targeted with DEC-205:OVA
could also present antigen to T cells in situ, we transferred
2  106 CFSE-labeled, antigen-specific T cells (CD8
OT-I cells) 1 d before injection with DEC-205:OVA,
isotype:OVA, or soluble OVA. After 3 d, the lymph nodes
(Fig. 3 E), spleen, and blood (data not depicted) were evaluated for OT-I proliferation as assayed by CFSE dilution.
Virtually all of the OT-I cells in lymph node entered cell
cycle and underwent 3–7 cell divisions after a dose of just
1.0 g of DEC-205:OVA conjugate ( 100 ng OVA)
per mouse (Fig. 3 E). For soluble OVA, at least 400-fold
more protein was required to induce comparable proliferative responses, and, again, the isotype-control:OVA conjugate elicited little or no proliferation (Fig. 3 E). To
prove that DEC-205 but not Fc receptors were mediating presentation, we verified that presentation was abol-

Downloaded from jem.rupress.org on April 1, 2015

Figure
2. Targeting
of
DEC-205:OVA to CD11c
lymph node DCs in vitro. (A)
DEC-205:OVA elicits stronger presentation than OVA alone
in a dose-dependent manner.
CD11c cells from C57BL/6
lymph nodes were cultured 18 h
in graded doses of DEC-205:
OVA or OVA alone, washed,
and cocultured with OT-I or
OT-II T cells before measuring
uptake of [3H]thymidine at 48–
72 h to assess T cell proliferation.
(B) Presentation of peptides derived from DEC-205:OVA is
restricted to CD11c lymph
node cells, and not the CD19
or CD11cCD19 (double negative) fractions. As in A, but with
DEC-205:OVA or the isotype:
OVA conjugate at 10 g/ml. (C)
Presentation of peptides derived
from DEC-205:OVA is TAP
dependent. As in B, but CD11c
cells were prepared from
C57BL/6 or TAP/ mice. (D)
Bone marrow DCs are unable to
present DEC-205:OVA on
MHC class I products. Cells
from d6 cultures were harvested
and cultured with antibody:OVA
conjugates for 6 h at 10 g/ml,
washed, and cocultured with T
cells as in panel A. Data are representative of three experiments.
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ished with DCs from DEC-205/ mice (data not
depicted). In summary, DEC-205 efficiently targets antigens for presentation by the exogenous pathway to MHC
class I in vivo.
DEC-205:OVA Does Not Mature DCs In Vivo. To
examine whether DEC-205:OVA treatment results in
DC maturation in the presence or absence of OVA-specific
OT-I T cells, we did FACS® studies of DCs from mice injected with conjugates 1 or 3 d earlier under a variety of
conditions. As illustrated in Fig. 4 A, surface expression of
CD80, CD86, as well as MHC class II products were unchanged in DEC-205:OVA-injected mice, whether or
not they received OT-1 T cells. The number of DCs also
did not change in mice given DEC-205:OVA. However,
coadministration of an agonistic CD40 antibody (FGK1632

45.5) as an adjuvant activated the DCs in situ over a 3 d period and increased their numbers about twofold. The extent of maturation with CD40 was similar in the absence
or presence of antigen (DEC-205:OVA) or OT-I T cells
(Fig. 4 A). Maturation was detected in CD11c DCs that
had low and high levels of DEC-205, but the levels of
CD86 were higher in the DEC-205 high fraction (Fig. 4
B). In summary, although lymph node DCs in the steady
state express molecules used in T cell activation like CD86,
these DCs do not seem to differentiate further when exposed to DEC-205:OVA but do differentiate in response
to agonistic CD40 antibody.
Distinct T Cell Responses In Vivo to Antigen Presented in the
Steady State and CD40-based DC Maturation. To follow
the fate of the OT-I T cells that proliferated in response to
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Figure 3. Targeting of DEC-205:OVA
to lymph node CD11c DCs in vivo. (A)
Only CD11c lymph node DCs efficiently
present exogenous DEC-205:OVA, and
to a lesser extent OVA, to OT-I T cells.
C57BL/6 mice were injected with 4.0 g
(1.0 g/footpad) of DEC-205:OVA conjugate or 400 g (100 g/footpad) of soluble OVA subcutaneously 4 and 24 h before
sacrifice. The CD11c and CD11cCD5
(B cell) fractions were MACS® sorted from
lymph nodes and evaluated for presentation
to OT-I T cells as in Fig. 2 A. Peptide controls were performed with the highest titration of APCs (DCs, left; B cells, right) for
each group. (B) As in panel A but CD11c
DC’s were studied 1 and 4 d after injection
of 4.0 g (1.0 g/footpad) of antibody:
OVA conjugates subcutaneously. (C) Presentation by DCs of OVA peptides from
C57BL/6 but not TAP/ mice given 4.0
g (1.0 g/footpad) of IgG:OVA conjugates subcutaneously 4 d earlier. (D)
DEC-205:OVA elicits better presentation
of OVA derived peptides than other DCtargeted conjugates, each injected with 4.0
g (1.0 g/footpad) of IgG:OVA conjugates subcutaneously 4 d earlier. (E)
DEC-205:OVA induces stronger in vivo
proliferation of OT-I T cells than OVA
alone. C57BL/6 mice were injected intravenously with 2  106 CFSE-labeled OT-I
T cells and then graded doses of IgG:OVA
conjugates or OVA subcutaneously 24 h
later. 3 d after conjugate injection, lymph
nodes were harvested and the expansion of
CD8V2V5.1/5.2 cells evaluated by flow
cytometry for CFSE dilution. Each panel
represents two or more experiments.
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antigen targeted to DCs in vivo, we tracked the transferred
T cells by flow cytometry using a combination of CD45.1
and V5.1/5.2 markers, and we compared responses in the
steady state to those following CD40-induced DC maturation. At 3 d after DEC-205:OVA injection, we found
strong proliferative responses in the presence or absence
DC maturation (Fig. 5 A). However, CD40 treated mice
also showed greatly enhanced T cell production of IL-2
and IFN- (Fig. 5 B, bottom row).

When we followed the numbers of injected OT-I T
cells at 3 d and at 12–14 d in several lymphoid tissues (Fig.
6, A and B), we found that DEC-205:OVA in the steady
state first expanded the OT-I cells, but by 12–14 d, the T
cells were virtually entirely absent from lymph nodes,
spleen, or blood (Fig. 6 A, compare left and right panels,
and Fig. 6 B). However, if the DEC-205:OVA conjugate
was given with CD40, the OT-I cells expanded relative
to the PBS control (Fig. 6, A and B) or isotype-control:

Figure 5. Contrasting responses of OT-I T cells to DEC-205:OVA in the presence or absence of CD40-induced DC maturation. (A) CD40 has
little impact on DEC-205:OVA induced proliferation of OT-I T cells. As in Fig. 3 E, but mice were or were not given CD40 (100 g FGK45.5 subcutaneously). (B) Differential IL-2 and IFN- production by OT-I T cells in response to isotype:OVA or DEC-205:OVA with or without CD40. As
in panel A, but lymph node suspensions were restimulated in vitro with the cognate OT-I peptide for 5 h in the presence of brefeldin A (5 g/ml) before
staining for intracellular cytokine. Data are representative of three experiments.
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Figure 4. Maturation of DCs in vivo by
agonistic CD40 but not by DEC-205:
OVA. (A) C57BL/6 mice were injected
subcutaneously with PBS or 4.0 g (1.0
g/footpad) of DEC-205:OVA conjugate with or without CD40 (100 g
FGK45.5 subcutaneously), 1 and 3 d before
sacrifice. CD11c cells were sorted by
MACS® from lymph nodes and evaluated
by flow cytometry for expression of CD80,
CD86, and MHC class II. Prior to injection
of the OVA conjugate and CD40, the
mice were given PBS () or OT-I ()
cells. The bold symbols are mean fluorescence indices of the CD11c cells in the
presence of a maturation stimulus, while the
gray-bold at day 3 indicate a significant increase, consistent with maturation. (B) Illustrative FACS® data showing the maturation
of the DEC-205hi CD11c cells and DEC205loCD11c cells, in mice treated 3 d before with PBS and CD40 as in panel A.

Published December 16, 2002

OVA conjugate (data not depicted). Similarly, when IFN-
production was monitored by FACS® (Fig. 6 C) or by
ELISPOT assays (data not depicted), the combination of
DEC-205:OVA and CD40 induced a strong expansion
of cytokine producing effectors, whereas cytokine producing OT-I cells were virtually deleted from the lymph node
when mice had received DEC-205:OVA (Fig. 6 C). As it
was possible that T cells were being redistributed to tissues
in the steady state rather than undergoing true deletion, we
isolated cells from one large peripheral organ, the lung. In
mice exposed to DEC-205:OVA, we could not find any

OT-I T cells in the lung at day 10, but many OT-I cells
were found in the lungs of mice given DEC-205:OVA
plus CD40 (Fig. 6 D). The expanded numbers of cells in
the lymph nodes and lungs in response to DEC-205:
OVA plus CD40 included a large fraction of cells lacking
the CD62L selectin for lymph node homing, a typical feature of activated T cells (Fig. 6 D). In summary, delivery of
protein antigens to DCs leads to the deletion of MHC class
I–restricted T cells, but antigen delivered together with a
maturation stimulus, leads to T cell expansion, production
of IFN-, and export of T cells to peripheral tissues.
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Figure 6. Deletion of OT-I T
cells in response to DEC-205:
OVA in steady state. (A)
C57BL/6 mice were given
CD45.1 OT-I T cells and antigen as described in 3E with or
without CD40. 3 and 12 d
later, lymph nodes, spleen, and
blood were harvested and evaluated for OT-I T cells
(CD45.1V5.1/5.2) by flow cytometry. (B) Data on the number of OT-I cells, expressed as
the mean percentage of CD8 T
cells from three experiments of
the type shown in panel A. (C)
CD40-rescued OT-I T cells
are primed and secrete IFN-.
C57BL/6 mice were given OT-I
T cells and antigen as described
in panel A. 12 d after antigen administration, lymph nodes were
harvested and OT-I T cells evaluated for IFN- secretion as described in Fig. 5 B. (D) OT-I T
cells are not present in a peripheral non-lymphoid tissue, after
presentation of DEC-205:
OVA by DCs in the steady state,
in the absence of CD40 stimulation. As in panel A, but the
lung was harvested 10 d after antigen administration and the
OT-I cells were evaluated for expression of CD62L and CD45.1.
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Discussion
These findings extend the evidence that DCs in peripheral lymphoid organs are constitutively processing antigens

in the steady state, and that the consequences of this presentation is peripheral tolerance. With the identification of
an efficient receptor mediated pathway, DEC-205, it is
clear that small amounts of a soluble protein can lead to
presentation on MHC class I and tolerance of CD8 T
cells. Prior studies with soluble proteins have emphasized
the need for high doses of antigen to tolerize the immune
system, and primarily on MHC class I products.
The DEC-205 endocytic receptor has several valuable
roles in antigen uptake and processing by DCs. First, the
receptor targets to MHC class II, late endosomal/lysosomal compartments in cultured bone marrow–derived DCs
(31). In contrast, most recycling endocytosis receptors traffic through peripheral or early endosomes. The late endosomal/lysosomal targeting of DEC-205 is associated with
much more efficient antigen processing and presentation
via the MHC class II pathway. These properties are mediated by the cytosolic domain of DEC-205, particularly an
acidic EDE sequence (31). Second, DEC-205 antibodies
in small amounts ( 1 g/mouse) can be used to target antigens for presentation by DCs in vivo. When an antigenic
peptide from hen egg lysozyme is engineered into the
heavy chain of the DEC-205 antibody, the antibody and
peptide is selectively delivered to DCs (32). Here, DEC205 has been chemically conjugated to full length OVA
and delivers the protein selectively to DCs in vivo as well.
Third, we now find that DEC-205 mediates presentation
of protein antigens via the exogenous but TAP-dependent
MHC class I pathway. Uptake via DEC-205 corroborates
that lymph node DCs in the steady state are capable of processing antigens onto MHC class I (35, 39–42) as well as
MHC class II (18, 32) products. In contrast, we do not obFigure 7. DEC-205:OVA
induces peripheral tolerance to
OVA in the steady state. (A)
C57BL/6 mice were given
CD45.1 OT-I T cells and antigen as described in 3E with or
without CD40. 12 d after antigen administration, mice were
boosted with 50 g of OVA
protein in complete CFA. After
3 d, lymph nodes were harvested
and OT-I T cells evaluated for
secretion of IL-2 (top) or IFN-
(bottom) as in Fig. 5 B. (B)
C57BL/6 mice were treated as
in panel A, but 3 d after administration of OVA in CFA, mice
were injected intravenously with
a mixture of CFSE-labeled syngeneic splenocytes pulsed with
(CFSEhi) or without (CFSElo)
the OT-I cognate peptide (3 
106 of each). 12 h later the loss of
CFSEhi cells in lymph nodes was
evaluated as a measure of specific
CTL activity. Naive mice do
not exhibit any loss of CFSE labeled cells (not shown). The results are representative of three
experiments.
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Antigen Targeting to DCs Induces Peripheral CD8 T Cell
Tolerance. A critical criterion for the induction of peripheral tolerance is the inability to respond to rechallenge with
antigen delivered together with a strong adjuvant. To determine whether DEC-205:OVA treated mice become
tolerant to OVA, we immunized with 50 g of OVA protein suspended in CFA 12 d after administration of the
conjugate. 3 d after OVA in CFA immunization, mice
were killed and the immune response was evaluated using
either ELISPOT assays (data not depicted) or FACS® assays
for intracellular cytokine production (Fig. 7 A). Control
mice pretreated with PBS or isotype-control:OVA were
able to be primed to OVA in CFA (Fig. 7 A). In contrast,
mice pretreated with DEC-205:OVA were unable to respond to OVA challenge (Fig. 7 A, top right panel in each
group). These same mice could be immunized to nonOVA proteins, e.g., the PPD antigen in the CFA (data not
depicted). We further assessed formation of effector CTL
using a recently described in vivo assay for CTL function
(35). Mice tolerized 12 d earlier with DEC-205:OVA
could not form CTL, but mice given PBS or the combination of DEC-205:OVA with CD40 produced strong
CTL responses (Fig. 7 B). We conclude that targeting antigens to DCs via DEC-205 in the steady state results in the
induction of peripheral tolerance, with no effector T cell
formation and memory, whereas targeting in the presence
of a DC maturation stimulus leads to immunization.
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proliferation. However, the T cells fail to differentiate and
are deleted unless a maturation stimulus also is provided.
To date, we have concentrated on CD40-based DC maturation. Nevertheless, the findings are consistent with the
view that the immunogenic function of DCs, i.e., the induction of effector T cells and the development of memory, requires that at least two sets of events take place. One
involves antigen capture and successful processing to form
MHC–peptide complexes; this occurs in lymph node DCs
in the steady state. The other requirement entails the intricate process of maturation, which changes DCs in many
ways, e.g., increasing T cell costimulatory molecules, inducing cytokines like IL-12 and IL-2, and altering the expression of chemokine receptors.
Two pathways have been defined for the presentation of
antigens on MHC class I products. The classical or “endogenous” pathway originates from newly synthesized proteins
especially those derived from defective ribosomal initiation
products (51). This pathway provides an elegant and established mechanism for protective immunity, guiding MHC
class I–restricted cytotoxic T lymphocytes to peptides produced in infected and malignant cells. By recognizing
MHC–peptide complexes displayed at the cell surface, the
CD8 cytolytic response is focused on cells harboring
pathogens and not on innocent bystander cells (52). A second “exogenous” pathway also exists, allowing endocytosed nonreplicating proteins to be presented on MHC
class I. The exogenous pathway a priori could allow noninfected cells to take up protein and become targets for
MHC class I–specific, CD8 cytolytic T lymphocytes. This
potentially serious problem would be averted if the exogenous pathway were primarily expressed in DCs. During infection, the processing of dying infected cells by the exogenous pathway provides a means for DCs to initiate CD8
T cell immunity to pathogens that do not productively infect them. Likewise, during the steady state, DCs in lymphoid organs can use the exogenous pathway to present
self-peptides on MHC class I (16, 40, 53; and this paper)
and thereby induce tolerance. Therefore the induction of
tolerance does not require that all cells be capable of processing antigens by the exogenous pathway; rather, the
presence of efficient receptors like DEC-205 for exogenous
presentation in vivo provides a specific mechanism for DCs
to continually delete the peripheral T cell repertoire of reactivity to low levels of self and environmental proteins.
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